Use of selinexor with ibrutinib to overcome ib... - CLL Support

CLL Support

23,253 members39,948 posts

Use of selinexor with ibrutinib to overcome ibrutinib resistance

1 Reply

New study involving the use of selinexor to overcome ibrutinib resistance is seen as a “breakthrough” by some people who are undoubtedly smarter than me. Interesting stuff, the plain English explanation is contained at “Breakthrough Increases Efficacy of B-Cell Lymphoid Malignancy Treatment”.

ajmc.com/newsroom/breakthro...

The far more complicated study itself is at “Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies”.

researchgate.net/publicatio...

I would like to think of this as a Christmas present for those of us who have encountered Ibrutinib resistance.

Merry Christmas,

Owen

Read more about...
1 Reply
lankisterguy profile image
lankisterguyVolunteer

Hi SlowCLL,

Thanks for posting those two links. Interesting reading for those of us that have developed resistance.

I'm actually resistant to Zydelig/Idelalisib and intolerant of side effects from Imbruvica/Ibrutinib, so I look for information like those papers.

Len

Not what you're looking for?

You may also like...

Hypertension and cardiovascular events following ibrutinib initiation

I thought it worth reiterating the high level of hypertension (HT) reported in patients treated...
Jm954 profile image
Administrator

YABTKi or Yet Another BTK inhibitor - the A to Z list of Bruton's Tyrosine Kinase Inhibitors for CLL following Ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
AussieNeil profile image
Partner

Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia ( CLL ) - Pseudo Richters

Several of us have reported our CLL symptoms have come roaring back after discontinuing...
AussieNeil profile image
Partner

BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies

Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Jm954 profile image
Administrator